Please assess the completion status of the following clinical trial:

Trial Title: Melatonin and the Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 30-79 years.~2. Diagnosed with metabolic syndrome according to AdenosineTriphosphate-III criteria.~3. Availability for six months after enrolling in the study.~Exclusion Criteria:~1. Inability to understand informed consent and to cooperate with study procedures.~2. Supplemental intake of melatonin.~3. Current smoking.~4. Current use of calcium channel blockers.~5. Current, planned, or recent (12 months) participation in another clinical trial.~6. Women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months.~7. Presence of any of the following diagnosed health conditions:~   * Active malignancy other than nonmelanoma skin cancer (current therapy for this malignancy,diagnosis within five years of enrollment, recurrence within five years of enrollment, or metastasis)~  * Uncontrolled hypothyroidism or hyperthyroidism~  * Recent (\< 1 year ago) history of heart attack, bypass surgery, angioplasty, or stroke~  * Heart failure (New York Heart Association functional class 3 or 4)~  * On renal dialysis~  * Immunosuppressive therapy (systemic corticosteroids, azathioprine, methotrexate, cyclophosphamide,~  * etc.) or an immunodeficiency syndrome~  * Narcotic or alcohol dependence~  * Obstructive sleep apnea (OSA) , defined either by previous diagnosis (with or without use of nasal CPAP), or by a score of 0.80 or higher on the MAP (Multivariate Apnea Prediction), a validated screening algorithm with high positive and negative predictive value for identifying OSA.~8. Shift-workers.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Melatonin 8mg one hour before bedtime for 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered 1 hour before bedtime for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).